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Advanced glycation end products (AGEs) have been reported to cause neurodegeneration, senile plaque formation and spatial 
learning and memory deficits. There is much evidence describing the beneficial effects of aminoguanidine (AG) on the central nervous 
system; AG is able to inhibit the receptor for AGEs and beta-amyloid (Aβ) deposition in the brain, thus preventing cognitive decline 
and neurodegeneration. In this study, we investigated whether AG protects against ovariectomy-induced neuronal deficits and Aβ 
deposition in rats. Animals in the ovariectomy group (OVX) group, and those in the OVX+AG group were treated with AG (100 mg/kg/day) 
for 8 weeks. Learning and memory were evaluated using the electric Y maze. AGE and Aβ1-40 biochemical assessments were performed 
using enzyme-linked immunosorbent assay (ELISA) kits. Furthermore, evaluations of brain amyloid precursor protein 695 (APP695) 
mRNA expression by RT-PCR and AGE expression by immunohistochemistry were carried out. Ovariectomized rats exhibited memory 
impairment and Aβ production disorder with upregulated APP695 mRNA and AGE expression levels. AG pretreatment relieved the 
ovariectomy-induced learning and memory disorder and significantly ameliorated the Aβ production disturbance and AGE generation. 
Additionally, pathological changes in morphology were also significantly recovered. Our data reveal that AG plays a  potentially 
neuroprotective role against ovariectomy-induced learning and cognitive impairment and Aβ production disorder.
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INTRODUCTION
In 2019 Alzheimer's disease International (ADI) es‑
timates that there are more than 50 million people are 
suffering from dementia globally, and the number is 
predicted soar to 152 million by 2050 (Alzheimer’s Dis‑
ease International, 2019). Increasing evidence has indi‑
cated that the oestrogen decline after menopause may 
influence learning and cognitive function, thus increas‑
ing the risk of Alzheimer’s disease (AD) (Fukuzaki et al., 
2008). So far, the characteristic pathogenesis of AD in‑
cluded the deposition of beta‑amyloid (Aβ), forming se‑
nile plaques and neurofibrillary tangles, disrupting syn‑
aptic plasticity and causing neuronal loss (Chen, 2018). 
Recently, growing evidence has suggested that ad‑
vanced glycation end products (AGEs) participate in the 
pathological processes of AD, including neurotoxicity 
and the aggregation of Aβ (Lubitz et al., 2016). AGEs are 
formed by the Maillard reaction and have been regarded 
as a primary source of neurotoxicity in Alzheimer’s dis‑
ease, which is affected by APP processing and Aβ forma‑
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tion via oxidative stress, resulting in the upregulation of 
cell apoptosis‑related signalling pathways (Ko et al., 2015). 
However, preclinical and animal studies have revealed 
that AGEs mediate the estrogens dysfunction that occurs 
during onset of AD and participate in cognitive damage in 
peri‑ and post‑menopausal women (Merhi, 2014).
Since a cohort study demonstrated that delayed hor‑
mone therapy after menopause accelerated the progres‑
sion of dementia in women, researchers have attempted 
to discover the relationship between oestrogen and AD 
(Merlo et al., 2017). Accumulating evidence suggests 
that oestrogen has a protective effect against the patho‑
genesis of AD by regulating Aβ accumulation, inhibiting 
Aβ‑mediated neurotoxicity, and enhancing Aβ clearance 
(Grimm et al., 2012). States of abnormal oestrogen lev‑
els during ageing are likely to cause aberrant astroglio‑
sis and neuroinflammation‑related neuronal cell death 
and interrupt cell‑cell interactions (Yun et al., 2018). 
Sarkar et al. (2015) discovered that the oestrogen‑in‑
duced amelioration of Aβ‑induced damage in mitochon‑
dria is regulated by mitochondrial signalling pathways 
and oxidative phosphorylation involving estrogen re‑
ceptor (ER) β and A kinase anchoring protein (AKAP). 
Further research suggested that oestrogen may protect 
against learning and memory impairment through the 
regulation of Aβ deposition and neuroinflammation by 
inhibiting nuclear factor kappa B (NF‑κB) activity in 
both neuroglial and neuronal cells (Yun et al., 2018).
Aminoguanidine (AG), an AGE inhibitor, is a low‑mo‑
lecular‑weight compound that exhibits selective sup‑
pression of inducible nitric oxide synthase (iNOS) and 
scavenges reactive oxygen species (ROS) (Pintus et al., 
2018). AG is considered to have diverse pharmacological 
activities, such as the ability to repair tissue damage, 
prevent brain injury and stroke, and improve spinal 
cord motor function (Pearse et al., 2003; Di et al., 2008). 
It also inhibits Aβ‑induced nuclear factor (NF)‑κB p65 
from translocating into the cytosol and prevents Aβ‑in‑
duced neurological disorders through reducing the 
expression of iNOS and Cyclooxygenase‑2 (COX‑2) and 
inactivating NF‑κB (Chen et al., 2017). To summarize, 
due to the anti‑inflammatory and neuromodulatory ad‑
vantages of AG, we considered it worthwhile to investi‑
gate the effects of AG on oestrogen deficiency‑induced 
learning and cognitive impairment and Aβ production 
mediated by AGEs, which have not yet been reported.
In the present study, to verify the hypothesis and 
deduce the underlying mechanisms, a rat model of ova‑
riectomy‑induced neuronal deficits and Aβ deposition 
was established. The effects of AG on memory impair‑
ment, Aβ production and the mRNA expression levels 
of APP and AGEs in tissues, serum and urine were de‑
tected. In addition, to investigate the effects of AG on 
morphological changes in the cerebral cortex and hip‑
pocampus, paraffin sections were observed after being 
stained with haematoxylin and eosin (HE).
METHODS
Animals and reagents
This study was approved by the Hebei Provincial 
Hospital of Traditional Chinese Medicine Ethics Com‑
mittee and all the experiments were carried out at re‑
search institute of this hospital. Adult female SD rats 
weighing 250‑300 g (SPF grade) were supplied by the Ex‑
perimental Animal Center of Beijing University of Chi‑
nese Medicine, China (license number SYXK (Beijing) 
2012‑0001). The animal studies abided by the guidelines 
established by the Chinese Committee on Experimental 
Animal Supervision. The study was a total of 36 rats, af‑
ter one week of adapted to the lab conditions, animals 
were randomly divided into three experimental groups, 
with each group containing 12 rats. The rats were 
housed 3 per cage in transparent polysulfone cages (59 
× 38 × 20 cm) containing wood‑chip bedding and nest‑
ing material. The animals were maintained on standard 
laboratory diet and water ad libitum, and were housed 
under controlled conditions of temperature (23±2°C), 
humidity (50±10%), air system filtration (10‑20 ventila‑
tions/hour) and on a 12 h : 12 h light : dark cycle. 
The rats were randomly assigned to one of the three 
following groups: the sham group (sham); the ovariecto‑
my group (OVX); and the aminoguanidine group (OVX‑
+AG). Animals in the OVX group underwent bilateral 
ovariectomy, and those in the sham group underwent 
sham surgery. Four weeks after the surgery, animals in 
the OVX group were randomly assigned to one of two 
groups, with ten animals in each group (four rats died). 
Animals in OVX group underwent gavage with saline, 
those in the OVX+AG group was administered an aque‑
ous solution of AG, and those in the sham group were 
also infused with saline. Finally, rats in each experimen‑
tal group (n=10‑12) were studied. AG (Sigma, St. Louis, 
MO, USA) was dissolved thoroughly in sterile water and 
given to the animals every morning at 09:00 a.m. The 
0.1% AG dose delivered to each animal was calculated as 
100 mg/kg/day for 8 weeks (Díaz et al., 2014). Then the 
rats were tested using the electric Y maze.
Electric Y maze
The spatial learning and memory of rats were eval‑
uated using the electric Y maze. The test was executed 
as explained by Amat et al. (2012) with subtle alter‑
ations. Briefly, the electric Y maze consisted of a con‑
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ductive grid floor with three identical arms (40 L × 10 W 
× 20 H cm) placed at 120° relative to each other; the 
arms were made of dark plexiglas. Two arms were un‑
safe zones, while the other was a safe zone. The rats 
were tested for two consecutive days; the correct es‑
cape rate was determined by the number of passes into 
the unsafe zones within ten repetitions, and the escape 
latency was determined by the time to the first pass 
into the safe zone from an unsafe zone.
ELISA 
After the behavioural evaluation, all survived ani‑
mals were humanely sacrificed at the 21th week of the 
experiment by an intraperitoneal injection of 5% chlo‑
ral hydrate (0.4 mL/kg). The urine was collected and 
blood was sampled from the abdominal artery, and 
both samples were stored at ‑80°C. Then, the rats were 
sacrificed and the brain was excised. One side of the 
hippocampus and cerebral cortex was rapidly stored 
at ‑80°C for future use, while the other side was fixed 
with 4% paraformaldehyde. The Aβ1‑40 levels in the hip‑
pocampus and cerebral cortex were determined using 
ELISA kits (AnaSpec, USA) according to the manufac‑
turer’s instructions. The AGE levels were determined 
using ELISA according to the method by Vitek et al., 
1994. Briefly, minced hippocampus and cerebral cor‑
tex tissues were dissolved in PBS (phosphate‑buffered 
saline; 0.01 mol/L, pH 7.0‑7.2), and the homogenates 
were centrifuged for 20 min at 5000 g. Then, the re‑
sultant suspension (100 ml) was added to a 96‑well 
plate, 100 μL/well, covered with the appropriate pu‑
rified AGEs (1:2000) and Aβ1‑40 (1:1000) antibody and 
incubated for 120 min at 37°C. The standard curve of 
AGEs and Aβ1‑40, at a concentration of 0.05~400 μg/mL 
and 970~11,285 pg/mL, respectively. The samples in the 
96‑well plate were rapidly measured at 450 nm using 
a microplate reader (Tecan, Switzerland). After three 
repeated measurements, the mean and standard devia‑
tion were calculated for the tested samples.
Fluorescence measurements
Additionally, the serum and urine AGE levels were 
quantified using immunofluorescence technique based 
on the Edelstein’s protocol (Edelstein and Brownlee, 
1992). The serum and urine were centrifuged for 20 min 
at 3000 g, solution was diluted at 1:10 by saline solution. 
The fluorescence intensity of AGEs in serum and urine 
was obtained at 380 nm excitation and 420 nm emission 
wavelengths using a spectrophotometer. The excitation 
and emission bandwidths were 5 and 10 nm, respective‑
ly. Fluorescent AGE (Fluo‑AGE) levels are expressed in 
arbitrary units. Moreover, the ELISA for AGE detection 
preferentially quantifies nonfluorescent AGEs (N(ε)‑car‑
boxymethyllysine (CML)) (Rondeau and Bourdon, 2011). 
The solution was centrifuged for 20 min at 3000 g, serum 
was diluted at 1:400, and urine was diluted at 1:10. The 
other steps were the same as those described above. 
Reverse transcriptase polymerase chain reaction 
(RT‑PCR)
The RNA of APP695 in the hippocampus and cerebral 
cortex was refined using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA). APP695 and glyceraldehyde‑phos‑
phate dehydrogenase (GAPDH) mRNA expression levels 
were analysed by RT‑PCR. RT‑PCR was performed using 
a reverse transcriptase kit (Promega Corporation, Mad‑
ison, WI, USA). All primers were designed and synthe‑
sized by Shanghai Sangon Biotech, China. The primer 
sequences are shown in Table I. FluorChem FC2 soft‑
ware (Alpha Innotech, CA, USA) was used to photo and 
analyze the gray value of the mRNA expression in each 
group. The RT‑PCR protocol conformed to that report‑
ed in our previous study (Xi et al., 2012).
Histological and immunohistochemical methods
The hippocampus and cerebral cortex were fixed 
with 10% formalin solution and then embedded in par‑
affin. The paraffin blocks were sectioned at 5 μm and 
stained with haematoxylin and eosin (HE). The stained 
tissues were observed using a Leica DM‑LS microscope 
at 40× and 400× magnification. Immunohistochemi‑
cal staining was performed as previously described 
(Hwang et al., 2015). At the end of the study, the brain 
was fixed in 4% paraformaldehyde for 24 h, soaked in 
70% ethanol and embedded in paraffin. The sections 
(20 μm) of the hippocampus and cerebral cortex were 
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Table I. Primer sequences and annealing temperature.
Primer Forward sequence (5’-3’) Reverse sequence (5’-3’) Annealing temperature (°C)
GAPDH CCCACGGCAAGTTCAACGGCA TGGCAGGTTTCTCCAGGCGGC 59
APP695 GACTCCGATGTCTGGTGGGG TGTCAGCTTTGGGCAAATTCTT 58
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immunostained using a peroxidase anti‑peroxidase 
method with DAB as the chromogen. Primary antibody 
incubation was performed using anti‑AGE antibody 
(Abcam, Cambridge, (MA) USA) at a 1:500 dilution over‑
night at 4°C. After rinsing with phosphate‑buffered sa‑
line (PBS), a secondary rabbit anti‑rat antibody（Invit‑
rogen, USA（was added, as was diaminobenzidine (DAB) 
for colour development. The AGE expression levels in 
the brain were assessed based on the greyscale den‑
sity per high‑power field (HPF) determined using im‑
age analysis software (Leica QWin Standard V 2.8, UK). 
Photomicrographs were obtained using a digital cam‑
era system (AxioCam Imager; Carl Zeiss) and a confocal 
laser scanning microscope at 400× magnification.
Statistical analysis
All data are shown as the mean ± standard deviation 
(SD) for all experiments. Differences between groups 
were analysed using the Statistical Package for Social 
Science (SPSS) 22.0 (SPSS, Inc., Chicago, USA) software 
package and one‑way analysis of variance (ANOVA) fol‑
lowed by SNK or scheffé’s multiple comparison test. All 
statistical analyses were 2‑sided, and significant differ‑
ences were considered at P<0.05.
RESULTS
Effects of AG on ovariectomy‑induced memory 
impairment in rats
To explore the effects of AG on spatial learning and 
memory impairment, rats in each experimental group 
(n=10‑12) were assessed using the Y maze task. Rats in 
the OVX group exhibited a remarkably reduced correct 
escape rate compared with those in the sham group (P< 
0.01), and an increasing rate was observed in the OVX‑
+AG group compared with the OVX group (F=5.162; df=2; 
P=0.014) (Fig. 1A). Rats in the OVX+AG group showed 
a significantly shorter escape latency than rats in the 
sham and OVX groups (F=3.842; df=2; P=0.036) (Fig. 1B).
Effects of AG on ovariectomy‑induced 
Aβ production in rats
Compared with the sham group, the Aβ1‑40 content 
in the cerebral cortex was increased in the OVX group 
(F=3.134 df=2; P=0.062); moreover, the Aβ1‑40 content 
in the hippocampus exhibited no significant changes 
(P=0.123). After treatment with AG, the Aβ1‑40 content in 
the cerebral cortex (P<0.01) and hippocampus (P<0.05) 
was significantly diminished compared with after OVX 
(F=5.290; df=2; P=0.008) (Fig. 2).
As shown in Fig. 3, APP695 mRNA expression was up‑
regulated in the OVX group in both the cerebral cor‑
tex and hippocampus compared with that in the sham 
group (P<0.01). However, AG remarkably downregulat‑
ed APP695 mRNA expression in the cerebral cortex and 
hippocampus compared with OVX (P<0.01) (Fig. 3).
Effects of AG on ovariectomy‑induced 
AGE changes
The AGEs contents of the cerebral cortex and hippo‑
campus in the OVX group were showed not significant‑
ly different from those in the sham group (P>0.05). Af‑
ter treatment with AG, the AGE content in the cerebral 
A
B
Fig. 1. Effects of AG on ovariectomized rats learning and memory change. 
(A) Correct escaping rate, (B) Escape latency were measured using the 
Y-electric maze. All data are shown as mean ± SD (n=10-12 per group). 
#P<0.05 compared with the sham group; ##P<0.01 compared with the sham 




cortex significantly declined (F=3.053; df=2; P=0.039) 
(Fig. 4A).
The AGE contents in the serum were significantly in‑
creased in the OVX group compared with the sham group 
(F=4.046; df=2; P=0.03), but no significant difference 
in the urine AGE contents was found between the two 
groups (P>0.05). Additionally, the urine AGE levels were 
significantly increased after treatment with AG com‑
pared to after the sham and OVX treatments (F=5.334; 
df=2; P=0.013). However, the two methods for detecting 
the serum AGE levels in the OVX+AG group showed dif‑
ferent results, with one level less than that in the OVX 
group (P<0.01) and the other significantly greater than 
that in the sham group (F=5.698; df=2; P=0.002) (Table II).
As shown in Fig. 4B, immunohistochemical staining 
indicated that AGE expression was significantly elevat‑
ed in the OVX group compared with the sham group 
(P<0.05). Moreover, the AGE levels were significantly low‑
er in the OVX+AG group than in the OVX group (P<0.05).
Effect of AG on ovariectomy‑induced 
morphological changes in the rat cerebral 
cortex and hippocampus
In the sham group, the structures of the cerebral 
cortex and hippocampus were normal, the nucleus and 
A
B
Fig.  2. Contents of Aβ in the hippocampus (A) and cerebral cortex (B) 
in each group. All data are shown as mean ± SD (n=10-12 per group). 
#P<0.05 compared with the sham group; ##P<0.01 compared with the 
sham group. *P<0.05 compared with the OVX group; **P<0.01 compared 
with the OVX group.
A
B
Fig. 3. The mRNA expressions of AGEs in the hippocampus (A) and cerebral 
cortex (B) in each group by RT-PCR. All data are shown as mean ± SD 
(n=10-12 per group). #P<0.05 compared with the sham group; ##P<0.01 
compared with the sham group. *P<0.05 compared with the OVX group; 
**P<0.01 compared with the OVX group.
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A
B
Fig. 4. Levels of AGEs in the hippocampus and cerebral cortex of the studied groups (A). The AGEs immune-positive expression in brain tissues of each 
group (B). All data are presented as mean ± SD (n=10-12 per group). #P<0.05 compared with the sham group; ##P<0.01 compared with the sham group. 
*P<0.05 compared with the OVX group; **P<0.01 compared with the OVX group.
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membrane of neural cells exhibited integrity, and the 
hippocampal pyramidal cells were aligned in an or‑
derly manner. In contrast, in the OVX group, the ce‑
rebral cortex and hippocampus showed diffuse shrink‑
age, widened sulci and enlarged ventricles; additional‑
ly, vacuoles in the neurons and reduced cell membrane 
integrity were identified. In the OVX+AG group, the 
pathological changes in morphology observed in the 
OVX group were significantly recovered (Fig. 5).
DISCUSSION
Until now, the pathogenic process that causes AD 
has not been fully understood; however, several ge‑
netic and biochemical factors, such as APP mutations, 
Aβ deposition, tau protein hyperphosphorylation, in‑
flammation, oestrogen deficiency, oxidative stress and 
glycation, contribute to AD pathogenesis (Parihar and 
Hemnani, 2004). In recent decades, the neuroprotec‑
tive effects of estrogens against neuroinflammatory 
and neurodegenerative aberrations have been well 
reported by numerous researchers (Engler‑Chiurazzi 
et al., 2017). Clinical trials have shown that the inci‑
dence of AD in women is 2‑3 times higher than that in 
men, and the completion of menopause significantly 
increases the risk of cognitive impairment (Pike, 2017). 
A recent study using a rodent model showed that re‑
duced 17β‑oestradiol levels were related to cognitive 
impairment in ovariectomized rats, and further re‑
search suggested that a 17β‑oestradiol prodrug could 
effectively reduce Aβ levels (Tschiffely et al., 2016). In 
addition, estrogens not only affect synaptotoxicity, ox‑
idative stress and neuroinflammation but also directly 
affect neurons, as well as neuronal cells, astrocytes and 
microglia selectively (Ben Halima et al., 2016). AD‑as‑
sociated decreases in estrogens and the resulting mor‑
phological changes were observed in ovariectomized 
rats in our study. HE staining of cerebral cortex and 
hippocampal sections showed diffuse shrinkage, wid‑
ened sulci and enlarged ventricles, as well as vacuoles 
in neurons and reduced cell membrane integrity in the 
OVX group.
The results of the present study indicate that rats 
in the OVX group exhibited significant learning and 
cognitive impairment compared with those of rats in 
the sham group. We examined the effects of AG in rats 
with ovariectomy‑induced memory impairment us‑
ing the Y maze, which indicated the spatial learning 
ability and working memory of the rats. We observed 
that AG improved both spatial learning and memory, 
as evidenced by reductions in the escape latency and 
significant increases in the correct escape rate in the 
Y maze test. Our results were consistent with those 
of previous reports showing that ovariectomy led to 
spatial learning and memory impairment. Zakeri et 
al. (2019) suggested that ovariectomy influenced anx‑
iety‑like behaviour, working memory, and physical 
strength through the elevated plus maze, Y maze and 
swimming capacity test. Sarkaki et al. (2008) indicat‑
ed that OVX rats exhibited impaired performance in 
locating a hidden escape platform in the Morris wa‑
ter maze. In addition, Snihur et al. (2008) showed that 
OVX adult rats exhibited impaired spatial navigation 
in the Morris water maze, as measured by search time 
and direct and circular swim persistence times. How‑
ever, our results revealed that oestrogen deprivation 
(OVX group) had no effect on the escape latency, while 
it impaired the correct escape rate. Even though this 
result was inconsistent with previously published 
findings, numerous reasons could be offered to ex‑
plain these discrepancies. Djiogue et al. (2018) ob‑
served that ovariectomy had no significant effects 
on short‑term memory, indicating an indirect link 
between ovariectomy and long‑term memory effects. 
Yamada et al. (1999) reported that neither long‑term 
(3 months) nor short‑term (1 month) deprivation of 
oestrogen by ovariectomy caused significant impair‑
ments in spatial learning and memory in the water 
maze or spontaneous alteration behaviours in the 
Y‑maze. This finding suggests that short‑term memo‑
ry depends more on specific areas in the brain, while 
long‑term memory relies on hippocampal formation in 
mammals and that the oestrogen effects are area‑spe‑
cific and time‑of‑duration‑specific in the brain (Zhao 
et al., 2012; Kim and Frick, 2017). Thus, future studies 
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Table II. Levels of AGEs in serum and urine (x±s, n=10-12).
Groups
Fluorescent AGEs Anti-CML AGEs
Serum (AU/mgpr) Urine (AU/mgpr) Serum (U/ml) Urine (U/gpr)
Sham 1.26±0.04 2641.10±425.42 3.93±0.60 11.82±2.14
OVX 1.73±0.35# 2429.11±550.83 4.84±0.67# 13.60±2.48
OVX+AG 1.22±0.27** 3709.20±863.7*# 5.27±0.84## 17.91±3.69*#
# P<0.05 vs. sham, ## P<0.01 vs. sham; * P<0.05 vs. OVX, ** P<0.01 vs. OVX.
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A
B
Fig. 5. HE staining was used in paraffin-embedded sections of the hippocampus (A) and cerebral cortex (B) in each group (HE staining, light microscope, 
×40, ×100 and ×400).
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attempting to confirm the available data should con‑
sider multiple factors, including the specific area in 
the brain and experimental time of duration.
Aminoguanidine, a well‑known AGE inhibitor, is 
a nucleophilic hydrazine compound that prevents AGE 
formation. AG has been reported to inhibit inflam‑
matory reactions and reduce potential neurodegen‑
eration in numerous experimental dementia models 
(Rodrigues et al., 2009). It has also been suggested 
that AG prevents cognitive impairment and reduces 
glial activation in the brain of mice with dementia in‑
duced by streptozotocin. Additionally, the beneficial 
effects of AG on the CNS include the suppression of 
AGE receptors in the brain, thus preventing learning 
and cognitive function decline and Aβ deposition in 
mice subjected to transverse aortic coarctation (TAC) 
(Carnevale et al., 2012). The present study aimed to 
illuminate the possible mechanisms underlying the 
neuroprotective effects of AG, such as the inhibition of 
ovariectomy‑induced neuronal deficits in rats via the 
inhibition of AGE‑mediation modulation of Aβ produc‑
tion. Ovariectomized rats can be considered models 
that imitate many cellular and molecular changes in 
neurodegenerative diseases, such as AD and Parkin‑
son’s disease. Simultaneously, decreasing estrogens 
levels might be followed by Aβ accumulation and hip‑
pocampal volume loss, which in turn play key roles in 
neurodegeneration (Mosconi et al., 2018).
Several observations suggest that AD is character‑
ized by toxic Aβ produced by β‑secretase (BACE1)‑me‑
diated cleavage of APP, and the accumulation of Aβ 
might trigger the pathological activation of APP sig‑
nalling, leading to neuronal dysfunction (Lan et al., 
2015; Bignante and Lorenzo, 2018). APP, a precursor 
of Aβ that also binds Aβ fibrils, mediates neurotox‑
ic effects on neuronal growth and subsequently ex‑
tends, resulting in diverse Aβ assemblies. Moreover, 
there have been reports demonstrating that Aβ‑de‑
rived ligands and Aβ oligomers extracted from the 
human brain in AD impair long‑term potentiation 
and partially accelerate neurofibrillary tangle (NFT) 
formation (Fukuzaki et al., 2008). In this study, ova‑
riectomized rats showed increased levels of APP695 
mRNA expression and significantly increased Aβ1‑40 
levels in the cerebral cortex. The increased expres‑
sion levels of APP and Aβ can partially account for the 
learning and memory impairments observed in these 
rats. AG (100 mg/kg/day) significantly decreased the 
levels of Aβ1‑40 and APP695 mRNA expression. Our re‑
sults are consistent with those of other researchers 
who verified that AG inhibits Aβ‑induced neurolog‑
ical disorders. However, we also found that OVX did 
not affect hippocampal Aβ1‑40 levels. Consistent with 
our findings, several studies have demonstrated that 
serum Aβ1‑40 levels were elevated in OVX animal 
models, although there was no effect on hippocam‑
pal Aβ1‑40 levels (Wang et al., 2017). These findings 
suggest that brain Aβ accumulation depends on not 
only ovarian hormonal decline but also complex reg‑
ulation in the brain.
An increasing number of studies have shown that 
ovariectomy in vivo causes learning and memory im‑
pairments through the modulation of Aβ deposition, 
neuroinflammation and other mechanisms (Yun et al., 
2018). There is also growing evidence that AGEs may 
affect the neuropathological and biochemical features 
of neurodegenerative processes, such as increased 
protein cross‑linking, oxidative stress, and neuronal 
death (Uribarri et al., 2015). In vivo, AGEs are com‑
bined with deposits of proteins, such as Aβ, resulting 
in plaque formation in the brain. In an AD‑like animal 
model, a high‑AGEs diet caused significant learning 
and memory impairments, insoluble Aβ42 and AGEs 
assembly in the hippocampus, and increased levels of 
oxidative stress. Lubitz et al. (2016) also reported that 
the AGEs receptor binds to Aβ42 and affects its trans‑
port across the blood‑brain barrier. Ko et al. (2010) 
demonstrated that AGEs regulate APP and APP syn‑
thesis pathways via ROS and enhance the deposition 
of Aβ. It is known that the soluble isoform binds to 
ligands and prevents the negative effects of receptor 
activation. Walker et al. (2015) demonstrated cogni‑
tive impairment, upregulated Aβ production, neuro‑
toxicity and inflammation in the neurons or microglia 
of transgenic mice overexpressing the receptor for 
AGEs (RAGE). Similarly, the ovariectomized rats in our 
study also showed upregulated APP, Aβ and AGEs lev‑
els, which caused spatial memory degeneration and 
morphological changes in the cerebral cortex and hip‑
pocampus. AG is itself a potent inhibitor of RAGE in 
the brain and thus prevents cognitive impairment and 
Aβ aggregation (Ben Halima et al., 2016). Our study 
shows that AG pretreatment prevents the memory 
deficits induced by ovariectomy because rats in the 
OVX+AG group demonstrated a reduced AGEs levels 
in the cerebral cortex and few morphological changes 
in the brain tissue, but hippocampal AGEs levels were 
not significantly changed (Fig. 4). Few studies have 
investigated the mechanisms by which AG promotes 
OVX‑induced neuronal deficits in rats. The current‑
ly‑accepted hypothesis is that AG mainly modulates 
Aβ production by inhibiting AGEs. However, the mech‑
anisms are unclear, and the complexity of brain‑neu‑
ral functions is unclear. Thus, further studies are re‑
quired to confirm these findings in the context of in‑
tegrating multiple factors, including the specific sites 
of action in the brain, experimental durations, and 
other potential reasons involved.
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CONCLUSION
In conclusion, our data reveal that AG relieved ova‑
riectomy‑induced learning and memory impairment in 
the hippocampus and cortex of rats. In our study, the 
neuroprotective effects of AG can be attributed to its 
anti‑AGEs activity and its ability to reduce the levels 
of Aβ and its precursor protein APP. However, further 
study is needed to determine the exact pathways and 
specific sites of action responsible for these effects.
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